Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Clinical trial NCT04373083 · WITHDRAWN
Trial details
- NCT number
- NCT04373083
- Sponsor
- Regeneron Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-15
- Primary completion
- 2022-12-20
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.